Published On: Sun, Aug 10th, 2014

Teva to sue Dr. Reddy’s over generic Copaxone

Teva confirmed that it will continue to vigorously defend its Copaxone intellectual property rights.

copaxone_03 TEVA

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has confirmed that it has received the first paragraph IV notice for a generic version of its three-times-a-week Copaxone 40 mg/mL treatment. Copaxone 40 mg/mL is protected by two Orange Book patents that expire in 2030.

The notice was from Dr. Reddy’s Laboratories Inc. and Teva said that it will continue to vigorously defend its Copaxone intellectual property rights against infringement wherever they are challenged. Teva said it plans to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of US Food and Drug Administration (FDA) approval of Dr. Reddy’s ANDA.

 

Share and Enjoy !

0Shares
0 0
Read more about: , , , , , , , , , , , , , , ,

Email:

Delivered by FeedBurner

Wordpress site Developed by Fixing WordPress Problems